Next Biomedical Co.,Ltd (389650) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Next Biomedical Co.,Ltd KRW 3,914, price KRW 31,750, upside -87.7%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Next Biomedical Co.,Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Next Biomedical Co.,Ltd. engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. It offers hemostatic material for endoscope; and microspheres for vascular embolization. The company was founded in 2014 and is based in Incheon, South Korea.
Stock analysis
Next Biomedical Co.,Ltd (389650) currently trades at 31,750 KRW, while our model-based Fair Value estimate is 3,914 KRW, 87.7% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 2,583 KRW (bear) to 4,892 KRW (bull), the price of 31,750 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Next Biomedical Co.,Ltd reported revenue of 16.5B KRW in FY2025 versus 2.3B KRW in FY2021, a compound +64.2%/yr. Reported net income was −311M KRW in FY2025.
Key figures
Market cap 258B KRW (≈ $192M) · P/S ratio 16.5 · Net margin −1.9% · Return on equity −0.1% · Return on assets (EBIT) −11.4% · Operating margin −28.9% · Revenue (TTM) 16.8B KRW · Revenue growth (YoY) +9.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 68% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −88%, 389650 screens richer than that median.
Fair Value models
Bear 2,583 KRWFair Value 3,914 KRWBull 4,892 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+72.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+80.6%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−307.4% (2021) → −4.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Next Biomedical Co.,Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score44 · Above median
Fair Value upside−87.7% · Bottom 25%
Profitability
Return on assets−1.3% · Above median
Net margin (TTM)−0.2% · Below median
Operating margin (TTM)−28.9% · Bottom 25%
Growth and dividend
Revenue growth9.2% · Above median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/S (TTM)0.01× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)46· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)99· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Next Biomedical Co.,Ltd (389650) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 3,914 KRW versus a price of 31,750 KRW, about −88% upside (overvalued).
What is the fair value of 389650?
Our model-based fair value for Next Biomedical Co.,Ltd is 3,914 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 31,750 KRW.
What is the quality score of 389650?
Next Biomedical Co.,Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Next Biomedical Co.,Ltd (389650)?
Our model-based price target is the fair value of 3,914 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 2,583 KRW, optimistic scenario 4,892 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Next Biomedical Co.,Ltd stock forecast for 2026?
Our models put fair value at 3,914 KRW, about −88% upside versus a price of 31,750 KRW (overvalued). Cautious scenario 2,583 KRW, optimistic scenario 4,892 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Next Biomedical Co.,Ltd (389650)?
Next Biomedical Co.,Ltd reported trailing-twelve-month revenue of about 16.8B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Next Biomedical Co.,Ltd (389650)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Next Biomedical Co.,Ltd it is 3,914 KRW per share (as of Sep 24, 2026), against a price of 31,750 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Next Biomedical Co.,Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 389650 trades above its calculated fair value: price 31,750 KRW, fair value 3,914 KRW, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 389650?
No. The price is what the market pays today (31,750 KRW); the fair value is what the company's own numbers justify (3,914 KRW). For Next Biomedical Co.,Ltd the two are 27,836 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Next Biomedical Co.,Ltd worth?
The market values Next Biomedical Co.,Ltd at about 258B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 31,750 KRW; our models calculate a fair value of 3,914 KRW per share.
What do the bullish and bearish scenarios say about 389650?
Our models span a range for Next Biomedical Co.,Ltd: cautious scenario 2,583 KRW, base 3,914 KRW, optimistic 4,892 KRW per share (as of Sep 24, 2026, price 31,750 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Next Biomedical Co.,Ltd (389650)?
Balance-sheet figures for Next Biomedical Co.,Ltd (as of Sep 24, 2026): return on equity −0.1%, debt of 0.02 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 389650 from its 52-week high?
Next Biomedical Co.,Ltd trades at 31,750 KRW, about 68% below its 52-week high of 98,000 KRW and 12% above the low of 28,300 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 3,914 KRW is for.
Which stocks are comparable to Next Biomedical Co.,Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Next Biomedical Co.,Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 31,750 KRW, calculated fair value 3,914 KRW (−88%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 389650 calculated?
We run Next Biomedical Co.,Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3,914 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Next Biomedical Co.,Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Next Biomedical Co.,Ltd (389650)?
The closing price on Oct 2, 2026 was 31,750 KRW. Our model-based fair value is 3,914 KRW, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Next Biomedical Co.,Ltd right now?
The price sits above even our optimistic bull case (4,892 KRW). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2,583 KRW to 4,892 KRW) leaves room in how you read the outcome.
Key figures of Next Biomedical Co.,Ltd
How large is the market capitalisation of Next Biomedical Co.,Ltd (389650)?
The market capitalisation of Next Biomedical Co.,Ltd is 258B KRW (≈ $192M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Next Biomedical Co.,Ltd (389650)?
The price-to-sales ratio of Next Biomedical Co.,Ltd is 16.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Next Biomedical Co.,Ltd (389650)?
The net margin of Next Biomedical Co.,Ltd is −1.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Next Biomedical Co.,Ltd (389650)?
The return on equity (ROE) of Next Biomedical Co.,Ltd is −0.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Next Biomedical Co.,Ltd (389650)?
On an EBIT basis the return on assets of Next Biomedical Co.,Ltd is −11.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Next Biomedical Co.,Ltd (389650)?
The operating margin of Next Biomedical Co.,Ltd is −28.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Next Biomedical Co.,Ltd (389650)?
Revenue at Next Biomedical Co.,Ltd is growing +9.2% versus a year earlier (3y avg +80.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Next Biomedical Co.,Ltd (389650) generate?
The free cash flow of Next Biomedical Co.,Ltd is −1.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Next Biomedical Co.,Ltd (389650) carry?
The net debt of Next Biomedical Co.,Ltd is 814M KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Next Biomedical Co.,Ltd in the live analysis
One click puts Next Biomedical Co.,Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
